middle.news
How Telix’s 63% Revenue Surge Fuels Its Radiopharma Pipeline Ambitions
9:09pm on Friday 29th of August, 2025 AEST
•
Healthcare
Read Story
How Telix’s 63% Revenue Surge Fuels Its Radiopharma Pipeline Ambitions
9:09pm on Friday 29th of August, 2025 AEST
Key Points
63% revenue growth to $390.4 million in H1 2025
Illuccix® approved in 23 countries with growing demand
Launch of Gozellix® with secured reimbursement in the US
R&D investment up 47% supporting late-stage therapeutics pipeline
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
TLX
OPEN ARTICLE